(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/076305 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61K 9/14* (2006.01)

(21) International Application Number:
PCT/US2022/047769

(22) International Filing Date:
25 October 2022 (25.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/271,977 26 October 2021 (26.10.2021) US

(71) Applicant: **OTSUKA PHARMACEUTICAL CO., LTD.** [JP/JP]; 2-9 Kanda Tsukasa-Machi, Chiyoda-Ku, Tokyo, Tokyo 101-8535 (JP).

(71) Applicant *(for SC only)*: **TANNER, Lorna** [US/US]; 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(72) Inventors: **GOODWIN, Aaron**; c/o Astex Pharmaceuticals, Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, California 94588 (US). **MADDINENI, Sindhuri**; c/o Astex Pharmaceuticals, Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, California 94588 (US). **DAVAR, Nipun**; c/o Astex Pharmaceuticals, Inc., 4420 Rosewood Drive, Suite 200, Pleasanton, California 94588 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: COMPOSITIONS COMPRISING AN ERK INHIBITOR

(57) Abstract: The present disclosure relates generally to compositions comprising Compound (I).





FIG. 1



(I)

WO 2023/076305 A1

[Continued on next page]

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*